Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI

Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference

HANGZHOU, China and SAN FRANCISCO, June 21, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide (XW003) in T2DM patients and from a Phase 1 study for oral ecnoglutide (XW004) in healthy and healthy obese participants, as well as preclinical data for novel amylin analog programs, at the American Diabetes Association (ADA) 84th Annual Conference.

Five posters, including one late-breaking poster, will be presented. The ADA conference is being held in Orlando, FL June 21-24, 2024. 

Late Breaking Poster Presentation (1871-LB): Saturday June 22, 12:30 PM - 1:30 PM
"Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide"

Poster Presentation (742-P): Sunday June 23, 12:30 PM - 1:30 PM
"A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes"

Poster Presentation (793-P): Sunday June 23, 12:30 PM - 1:30 PM
"Biased GLP-1 analog ecnoglutide (XW003) has improved efficacy relative to unbiased peptides"

Poster Presentation (789-P): Sunday June 23, 12:30 PM - 1:30 PM
"Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control"

Poster Presentation (788-P): Sunday June 23, 12:30 PM - 1:30 PM
"Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models"

About ecnoglutide

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for MASH.  Ecnoglutide is a novel, biased, long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly subcutaneous dosing. Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in Phase 1 through Phase 3 clinical studies.

About Sciwind

Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog XW003 (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs (preclinical). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com

SOURCE Hangzhou Sciwind Biosciences Co., Ltd.

These press releases may also interest you

at 03:45
ZWSOFT is proud to announce that ZWCAD, its flagship 2D CAD solution, has been awarded the Best Usability badge in G2's 2024 Summer Reports. In addition, ZWCAD now ranks first on G2's Easiest To Use General-Purpose CAD list. This prestigious...

at 03:19
TruDoc Healthcare, a telehealth leader, announced a partnership with e& enterprise to transform healthcare communications in the MENA region. This collaboration introduces the engageX solution, powered by the NICE CXone platform, setting a new...

at 03:05
Logitech International (SIX: LOGN) published its annual Fiscal Year 2024 Impact Report detailing the Company's progress toward its sustainability ambition. The Company reports continued product carbon reduction progress at scale by Designing for...

at 03:05
The faulty CrowdStrike Falcon Sensor update and subsequent outage ? the CrowdOut Event ? underscore the potential for Single Point of Failure (SPoF) technology outages to impact the global digital economy. CyberCube is advising clients on how to use...

at 03:05
Pepper Advantage is pleased to announce Mr Niall Sorohan's appointment as CEO of Pepper Advantage Ireland. Sorohan will take up his appointment on 01 January 2025, bringing with him over 20 years of experience in the financial services industry in...

at 03:05
Woodward, Inc. , a global leader in energy control solutions for aerospace and industrial applications, announced it has been selected to provide rotary actuation solutions for the NASA and Boeing Transonic Truss-braced Wing (TTBW) X-66A aircraft...

News published on and distributed by: